Consolidated revenue from operations of the company, however, rose to Rs 1,596.05 crore for the quarter under consideration as against Rs 1,453.92 crore for the same period year ago, it said.
"We have started FY 18 on a steady note, with our pharma segment recording its highest ever revenues during the quarter despite margin contraction in the US generics business", Jubilant Life Sciences Chairman Shyam S Bhartia and Co- Chairman & MD Hari S Bhartia said on the
The company continues to focus on operating cash generation to reduce its debt levels and strengthen the balance sheet, they added.
Shares of Jubilant Life Sciences today closed at Rs 703.70 on BSE, down 1.17 per cent from previous close.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.